Lessons learned from glycemia control studies

Current Diabetes Reports

Volumn 10, Issue 2, 2010, Pages 133-138

  Dokun, Ayotunde O ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Glucose; Glycemic control; Hyperglycemia; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; LIPID; METFORMIN;

BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CLINICAL STUDY; CRITICALLY ILL PATIENT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; LIPID ANALYSIS; MICROVASCULARIZATION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SAMPLE SIZE; COMPLICATION; CRITICAL ILLNESS; MICROVASCULATURE; PATHOLOGY; PERSONALIZED MEDICINE;

CRITICAL ILLNESS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; INDIVIDUALIZED MEDICINE; MICROVESSELS;

EID: 77953618346     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0094-6     Document Type: Review

References (36)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [no authors listed]. Lancet 1998, 352:837-853.
2. World Health Organization: Diabetes. Available at http://www.who.int/ mediacentre/factsheets/fs312/en/index.html. Accessed January 2010.
3. Centers for Disease Control and Prevention: National diabetes fact sheet: general information and national estimates on diabetes in the United States. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2007. http://www.cdc.gov/diabetes/pubs/pdfndfs-2007.pdf.
4. Barr EL, Zimmet PZ, Welborn TA, et al.: Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007, 116:151-157.
5. Krolewski AS, Warram JH, Valsania P, et al.: Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991, 90(Suppl 2A):56S-61S.
6. Fox CS, Coady S, Sorlie PD, et al.: Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007, 115:1544-1550.
7. Moss SE, Klein R, Klein BE: Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991, 81:1158-1162.
8. Bagshaw SM, Egi M, George C, et al.: Early blood glucose control and mortality in critically ill patients in Australia. Crit Care Med 2009, 37:463-470.
9. Selvin E, Marinopoulos S, Berkenblit G, et al.: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141:421-431.
10. Clement S, Braithwaite SS, Magee MF, et al.: Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004, 27:553-591.
11. van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in critically ill patients. N Engl J Med 2001, 345:1359-1367.
12. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
13. Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
14. Effects of intensive glucose lowering in type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes Study Group [no authors listed]. N Engl J Med 2008, 358:2545-2559.
15. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group [no authors listed]. N Engl J Med 2008, 358:2560-2572.
16. Intensive versus conventional glucose control in critically ill patients. The NICE-SUGAR Study Investigators [no authors listed]. N Engl J Med 2009, 360:1283-1297.
17. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979, 59:8-13.
18. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group [no authors listed]. N Engl J Med 2005, 353:2643-2653.
19. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854-865.
20. Holman RR, Paul SK, Bethel MA, et al.: 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
21. Turnbull FM, Abraira C, Anderson R, et al.: Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298.
22. Ray KK, Seshasai SR, Wijesuriya S, et al.: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
23. Mannucci E, Monami M, Lamanna C, et al.: Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009, 19:604-612.
24. Reaven PD, Moritz TE, Schwenke DC, et al.: Intensive glucose-lowering therapy reduces cardiovascular disease events in Veterans Affairs Diabetes Trial participants with lower calcified coronary atherosclerosis. Diabetes 2009, 58:2642-2648.
25. Levetan CS, Passaro M, Jablonski K, et al.: Unrecognized diabetes among hospitalized patients. Diabetes Care 1998, 21:246-249.
26. Umpierrez GE, Isaacs SD, Bazargan N, et al.: Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002, 87:978-982.
27. Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997, 314: 1512-1515.
28. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A: Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999, 67:352-360.
29. Furnary AP, Gao G, Grunkemeier GL, et al.: Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003, 125:1007-1021.
30. Garber AJ, Moghissi ES, Bransome ED Jr, et al.: American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract 2004, 10(Suppl 2):4-9.
31. Malmberg K, Ryden L, Wedel H, et al.: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005, 26:650-661.
32. Brunkhorst FM, Engel C, Bloos F, et al.: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358:125-139.
33. Van den Berghe G, Wilmer A, Hermans G, et al.: Intensive insulin therapy in the medical ICU. N Engl J Med 2006, 354: 449-461.
34. Van den Berghe G, Mesotten D, Vanhorebeek I: Intensive insulin therapy in the intensive care unit. CMAJ 2009, 180:799-800.
35. Griesdale DE, de Souza RJ, van Dam RM, et al.: Intensive insulin therapy and mortality among critically ill patients: a metaanalysis including NICE-SUGAR study data. CMAJ 2009, 180:821-827.
36. Moghissi ES, Korytkowski MT, DiNardo M, et al.: American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract 2009, 15:353-369.